Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INAB IN8bio	$2.26 -0.9%	$2.24	$1.98 ▼ $16.70	$10.26M	0.01	162,082 shs	32,513 shs
LVTX LAVA Therapeutics	$1.55	$1.43	$0.85 ▼ $2.09	$40.78M	0.5	204,335 shs	156,763 shs
MDCX Medicus Pharma	$2.00 -1.5%	$2.64	$1.80 ▼ $8.94	$35.64M	N/A	231,687 shs	423,586 shs
PYRGF PyroGenesis Canada	$0.21 -2.0%	$0.30	$0.21 ▼ $0.71	$38.58M	0.83	13,241 shs	35,513 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INAB IN8bio	+2.24%	+3.17%	-2.98%	-50.46%	-85.30%
LVTX LAVA Therapeutics	+1.97%	+1.64%	+1.97%	+17.34%	-16.22%
MDCX Medicus Pharma	-0.49%	-0.49%	-16.80%	-44.08%	+202,999,900.00%
PYRGF PyroGenesis Canada	-4.72%	-9.68%	-26.96%	-46.15%	-65.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INAB IN8bio	3.8941 of 5 stars	3.5	5.0	0.0	0.0	3.3	2.5	1.3
LVTX LAVA Therapeutics	2.0867 of 5 stars	3.0	5.0	0.0	0.0	2.7	0.0	0.0
MDCX Medicus Pharma	1.6902 of 5 stars	3.8	0.0	0.0	0.0	1.8	0.8	0.0
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INAB IN8bio	3.00	Buy	$180.00	7,864.60% Upside
LVTX LAVA Therapeutics	2.00	Hold	$2.69	73.23% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,075.00% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INAB, PYRGF, LVTX, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INAB IN8bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.40	N/A	N/A	$0.76 per share	2.04
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	4.22	N/A	N/A	($0.01) per share	-20.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INAB IN8bio	-$30.44M	-$9.11	N/A	N/A	N/A	N/A	-184.97%	-126.75%	11/11/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.05	N/A	N/A	N/A	N/A	-106.29%	-38.24%	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest INAB, PYRGF, LVTX, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/7/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INAB IN8bio	0.01	7.03	7.03
LVTX LAVA Therapeutics	N/A	10.78	10.78
MDCX Medicus Pharma	N/A	1.29	1.29
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INAB IN8bio	92.05%
LVTX LAVA Therapeutics	N/A
MDCX Medicus Pharma	N/A
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
INAB IN8bio	15.50%
LVTX LAVA Therapeutics	9.50%
MDCX Medicus Pharma	11.20%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INAB IN8bio	20	4.54 million	3.84 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data

INAB, PYRGF, LVTX, and MDCX Headlines

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results

August 6, 2025 | globenewswire.com

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

August 5, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What Happened

August 3, 2025 | marketbeat.com

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

August 1, 2025 | globenewswire.com

PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company

July 31, 2025 | globenewswire.com

PyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed Silica

July 28, 2025 | globenewswire.com

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

July 15, 2025 | globenewswire.com

PyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles

July 8, 2025 | globenewswire.com

PyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in Europe

July 2, 2025 | globenewswire.com

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - Morningstar

June 29, 2025 | morningstar.comM

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders

June 27, 2025 | globenewswire.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB, PYRGF, LVTX, and MDCX Company Descriptions

IN8bio NASDAQ:INAB

$2.26 -0.02 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$2.28 +0.02 (+0.66%)

As of 05:49 PM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

LAVA Therapeutics NASDAQ:LVTX

$1.55 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.55 0.00 (0.00%)

As of 04:47 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Medicus Pharma NASDAQ:MDCX

$2.00 -0.03 (-1.48%)

As of 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

PyroGenesis Canada NASDAQ:PYRGF

$0.21 0.00 (-2.05%)

As of 03:20 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time